Author

Stacy Wu

Observed names: Stacy S Wu, Wu, Stacy

Institution: Sumitomo Dainippon Pharma (United States)

Observed institutions: University Hospital of Basel, Novartis (United States), Sunovion (United States), Sumitomo Dainippon Pharma (United States)

ORCID: 0009-0000-8486-5893

Observed ORCID: 0009-0000-8486-5893

OpenAlex ID: A5076064307

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

2010 · Jeffrey A. Cohen, Frederik Barkhof, et al. · New England Journal of Medicine · 2,236

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

2011 · Bhupendra Khatri, Frederik Barkhof, et al. · The Lancet Neurology · 223

Treatment of Parkinson???s Disease

2005 · Stacy S Wu, Steven J Frucht · CNS Drugs · 79

Oromandibular dystonia as a complication of cerebrotendinous xanthomatosis

2009 · Roy Alcalay, Stacy Wu, et al. · Movement Disorders · 19

Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study

2024 · Jan Kassubek, Stewart A. Factor, et al. · Journal of Neurology · 15

Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson’s Disease: An Open-Label, Randomized, Crossover Study

2023 · Fabrizio Stocchi, Olivier Rascol, et al. · Journal of Parkinson s Disease · 14

Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study

2023 · Jan Kassubek, Fabrizio Stocchi, et al. · Therapeutic Advances in Neurological Disorders · 6

Works count: 10

Citation count: 2,592

H-index: 6

I10-index: 6